Research programme: DYRK inhibitors - Biosplice Therapeutics/ Novo Nordisk
Alternative Names: Dual specificity tyrosine phosphorylation-regulated kinase inhibitors - Biosplice Therapeutics / Novo NordiskLatest Information Update: 17 Jun 2024
At a glance
- Originator Biosplice Therapeutics
- Developer Biosplice Therapeutics; Novo Nordisk
- Class Antihyperglycaemics; Small molecules
- Mechanism of Action DYRK kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetes mellitus
Most Recent Events
- 13 Jun 2024 Biosplice Therapeutics and Novo Nordisk agree to co-develop DYRK inhibitors in USA for diabetes mellitus
- 13 Jun 2024 Preclinical trials in Diabetes mellitus in USA (PO) prior to June 2024
- 13 Jun 2024 Pharmacodynamics data from a preclinical studies in Diabetes mellitus released by Biosplice Therapeutics